the EVA15 Insufflator

Palliare announces US FDA 510(k) clearance to extend the indications of its EVA15 insufflation technology for use in endoscopic surgery

Retrieved on: 
Thursday, July 15, 2021
Health, Medical devices, Technology, Hospitals, Surgery, Hardware, Biotechnology, Medicine, Clinical medicine, Endoscopy, Medical terminology, Digestive system surgery, Laparoscopy, Diagnostic gastroenterology, Insufflation, Therapeutic endoscopy, AME Publishing Company, the EVA15 Insufflator, Palliare, THE EVA15 INSUFFLATOR, PALLIARE

Palliare, an emerging company with the vision to create a safer operating room, today announced that it has received FDA 510(k) clearance for its END-200 tubeset, which extends the capabilities of its EVA15 continuous pressure insufflation technology from laparoscopic surgery to endoscopic and endoluminal surgery.

Key Points: 
  • Palliare, an emerging company with the vision to create a safer operating room, today announced that it has received FDA 510(k) clearance for its END-200 tubeset, which extends the capabilities of its EVA15 continuous pressure insufflation technology from laparoscopic surgery to endoscopic and endoluminal surgery.
  • EVA15 is the first insufflator of its kind to be brought to market which will allow intelligent leak-tolerant constant pressure insufflation during endoscopic surgery, features that EVA15 currently offers for laparoscopic and robotic surgery.
  • For complex, long or high leak therapeutic endoscopy procedures, current insufflation requires careful ongoing management by the endoscopist.
  • Palliare was founded in 2018 as a spinout from Irish gastro-diagnostic company Crospon, which was acquired by Medtronic (NYSE:MDT) in 2017.

Palliare Completes $8m Series A Funding Round

Retrieved on: 
Monday, June 28, 2021
Professional services, Medical devices, Health, Surgery, Finance, Biotechnology, Supply chain management, Spinout, Jennifer McMahon, MDT, Subscription, New York Stock Exchange, Medtronic, Finance, Economy, the EVA15 Insufflator, Palliare, THE EVA15 INSUFFLATOR, PALLIARE

Palliare, an emerging company with the vision to create a safer operating room, today announced the closing of an oversubscribed $8 million Series A funding round.

Key Points: 
  • Palliare, an emerging company with the vision to create a safer operating room, today announced the closing of an oversubscribed $8 million Series A funding round.
  • With the close of the Series A round, Jennifer McMahon, Principal at Seroba, will join the board.
  • Jennifer commented, We are delighted to back the experienced Palliare team who have identified the clinical need for a user-friendly continuous pressure insufflator.
  • Palliare was founded in 2018 as a spinout from Irish gastro-diagnostic company Crospon, which was acquired by Medtronic (NYSE:MDT) in 2017.

Palliare Announces New Board Appointment

Retrieved on: 
Wednesday, February 17, 2021
Biotechnology, Surgery, Medical devices, Hospitals, Health, Spinout, MDT, Medtronic, New York Stock Exchange, Insufflation, Medicine, Health sciences, Health, the EVA15 Insufflator, Palliare

Palliare, an emerging company with the vision to create a safer operating room, is pleased to announce the appointment of Samantha Bonano to the Board of Directors.

Key Points: 
  • Palliare, an emerging company with the vision to create a safer operating room, is pleased to announce the appointment of Samantha Bonano to the Board of Directors.
  • Commenting on the new Board appointment, Scott Flora, Chairman, said, We are pleased to welcome Samantha Bonano to the Board.
  • With the pending US commercial release of our EVA15 insufflation and smoke evacuation system, her previous experience in developing a world leader in smoke evacuation will bring a valued mindset to the Board.
  • Palliare Ltd was founded in 2018 as a spinout from Irish gastro-diagnostic company Crospon, which was acquired by Medtronic (NYSE:MDT) in 2017.

Palliare Announces Organizational Changes

Retrieved on: 
Monday, December 7, 2020
Biotechnology, FDA, Surgery, Medical devices, Health, Medtronic, MDT, Spinout, the EVA15 Insufflator, Palliare, PORSAV

Palliare, an emerging company with the vision to create a safer operating room, has appointed John ODea as Group CEO.

Key Points: 
  • Palliare, an emerging company with the vision to create a safer operating room, has appointed John ODea as Group CEO.
  • Caroline ODea will continue in her current role as Managing Director of the Irish operation of Palliare.
  • Palliare Ltd was founded in 2018 as a spinout from Irish gastro-diagnostic company Crospon, which was acquired by Medtronic (NYSE:MDT) in 2017.
  • PORSAV (Protecting OR Staff from Aerosolized Virus) is an EU-funded project that emanated out of collaborative work between Palliare and Professor Ronan Cahill of University College Dublin.